Journal Mobile Options
Table of Contents
Vol. 14, No. 1, 2009
Issue release date: December 2008
Audiol Neurotol 2009;14:26–34

Long-Term Prognosis of Steroid-Dependent Sensorineural Hearing Loss

Kanzaki J. · Kanzaki S. · Ogawa K.
aDepartment of Otolaryngology, Keio University, School of Medicine, Shinjuku, Tokyo, and bDepartment of Otolaryngology, International University of Health and Welfare, Atami, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


We report on the long-term follow-up of 15 patients with steroid-dependent sensorineural hearing loss (SDSNHL), which was steroid dose dependent. We classified the patients into 2 groups: group A consisted of 6 patients with systemic SDSNHL, and group B consisted of 9 patients with inner-ear-specific SDSNHL without systemic disease. Group B patients were further classified as patients with slowly or rapidly progressive hearing loss. The yearly rate of hearing deterioration was greater in group B than in group A. Thus, the long-term hearing prognosis of patients in group B was worse than those in group A. Although SDSNHL may have immune-related origins, we hypothesize that hearing deterioration may be caused by proinflammatory cytokines because many of our cases exhibited abnormal immunological laboratory values and because many of these cases responded favorably to steroid treatment.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Adams JC: Clinical implications of inflammatory cytokines in the cochlea: a technical note. Otol Neurotol 2002;23:316–322.
  2. Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K, Okano H: Proinflammatory cytokines expression in noise-induced damaged cochlea. J Neurosci Res 2006;83:575–583.
  3. Gloddek B, Lamm K, Arnold W: Pharmacological influence on inner ear endothelial cells in relation to the pathogenesis of sensorineural hearing loss. Adv Otorhinolaryngol 2002;59:75–83.
  4. Harris JP, Sharp PA: Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;100:516–524.
  5. Hirose K, Westrum LE, Stone JS, Zirpel L, Rubel EW: Dynamic studies of ototoxicity in mature avian auditory epithelium. Ann NY Acad Sci 1999;884:389–409.
  6. Hughes GB, Moscicki R, Barna BP, San Martin JE: Laboratory diagnosis of immune inner ear disease. Am J Otol 1994;15:198–202.
  7. Ito T, Watanabe T, Aoyagi M: Atypical Cogan’s syndrome with steroid responsive sensorineural hearing loss. Audiol Jpn 2004;47:175–180.
  8. Jeong HJ, Hong SH, Park RK, Shin T, An NH, Kim HM: Hypoxia-induced IL-6 production is associated with activation of MAP kinase, HIF-1, and NF-κB on HEI-OC1 cells. Hear Res 2005;207:59–67.
  9. Kanzaki J, Ino T, Takahashi M: Clinical investigations on fluctuating hearing loss without vertigo. Audiol Jpn 1975;18:88–98.
  10. Kanzaki J, O-Uchi T: Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol 1981;230:5–9.
  11. Kanzaki J, O-Uchi IT: Circulating immune complexes in steroid-responsive sensorineural hearing loss and the long-term observation. Acta Otolaryngol 1983;393(suppl):77–84.

    External Resources

  12. Kanzaki J, O-Uchi T, Tsuchihashi N: Steroid-responsive sensorineural hearing loss: combination therapy with prednisolone and Sairei-to. ORL J Otorhinolaryngol Relat Spec 1993;55:24–29.
  13. Kanzaki J: Steroid responsive sensorineural hearing loss (in Japanese). Otol Jpn 1994a;4:146–153.
  14. Kanzaki J, Inoue Y, O-Uchi T: Immunological findings of serological tests in steroid-responsive sensorineural hearing loss. Acta Otolaryngol Suppl 1994b;514:66–69.
  15. Kanzaki J: Immune-mediated sensorineural hearing loss. Acta Otolaryngol Suppl 1994c;514:70–72.
  16. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS: Takayasu arteritis. Ann Intern Med 1994;120:919–929.
  17. Kunihiro T, Kanzaki J, O-Uchi T, Yoshida A: Steroid-responsive sensorineural hearing loss associated with aortitis syndrome. ORL J Otorhinolaryngol Relat Spec 1990;52:86–95.
  18. Kusakari C, Hozawa K, Koike S, Kyogoku M, Takasaka T: MRL/MP-lpr/lpr mouse as a model of immune-induced sensorineural hearing loss. Ann Otol Rhinol Laryngol Suppl 1992;157:82–86.
  19. Loveman DM, de Comarmond C, Cepero R, Baldwin DM: Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin Arthritis Rheum 2004;34:538–543.
  20. Masuda M, Nagashima R, Kanzaki S, Fujioka M, Ogita K, Ogawa K: Nuclear factor-kappa B nuclear translocation in the cochlea of mice following acoustic overstimulation. Brain Res 2006;1068:237–247.
  21. McCabe BF: Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585–589.
  22. Moscicki RA, San Martin JE, Quintero CH, Rauch SD, Nadol JB Jr, Bloch KJ: Serum antibody to inner ear proteins in patients with progressive hearing loss: correlation with disease activity and response to corticosteroid treatment. JAMA 1994;272:611–616.
  23. Nomura Y, Kitamura K: Abrupt (sharp cut) type sensorineural hearing loss – a human temporal bone study. Auris Nasus Larynx 1979;6:13–21.
  24. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G: Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999;100:55–60.
  25. Rarey KE, Luttge WG: Presence of type I and type II/IB receptors for adrenocorticosteroid hormones in the inner ear. Hear Res 1989;41:217–221.
  26. Raza K, Karokis D, Kitas GD: Cogan’s syndrome with Takayasu’s arteritis. Br J Rheumatol 1998;37:369–372.
  27. Siglock TJ, Brookler KH: Sensorineural hearing loss associated with Takayasu’s disease. Laryngoscope 1987;97:797–800.
  28. Smith JC, Peck JE, Ray LI, Smith EC: Aortoarteritis and sensorineural hearing loss in an adolescent black male. Am J Otolaryngol 2004;25:370–376.
  29. Sone M, Schachern PA, Paparella MM, Morizono N: Study of systemic lupus erythematosus in temporal bones. Ann Otol Rhinol Laryngol 1999;108:338–344.
  30. ten Cate WJ, Zuo J, Lautermann J, Altenhoff P, Rarey KE: Development of 11 beta-hydroxysteroid dehydrogenase expression in the rat cochlea. Acta Otolaryngol 1997;117:841–844.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50